Heparin-Binding Epidermal Growth Factor-Like Growth Factor as a Potent Target for Breast Cancer Therapy.
Heparin-binding epidermal growth factor-like growth factor (HB-EGF) belongs to the EGF family and exhibits its activity after binding to its receptors in autocrine, paracrine, and juxtacrine interactions. HB-EGF plays important roles in several biological and pathological processes, such as wound healing, blastocyst implantation, atherosclerosis, and heart development. Clinical studies have shown that HB-EGF is closely correlated with tumorigenesis, metastasis, and drug resistance in breast cancer. Specifically, targeted inhibition of HB-EGF improves the therapeutic efficacy and suppresses the tumor progression. This review discusses the importance of HB-EGF in mammary carcinoma progression and the potential value of HB-EGF as a therapeutic target for breast cancer treatment.
1 Institute of Life Sciences, Jiangsu University , Zhenjiang, China .
Caixia
C
Lian
2 School of Pharmacy, Jiangsu University , Zhenjiang, China .
Lingling
L
Ruan
1 Institute of Life Sciences, Jiangsu University , Zhenjiang, China .
Dongsheng
D
Shang
1 Institute of Life Sciences, Jiangsu University , Zhenjiang, China .
Yanfang
Y
Wu
2 School of Pharmacy, Jiangsu University , Zhenjiang, China .
Yongjin
Y
Lu
1 Institute of Life Sciences, Jiangsu University , Zhenjiang, China .
Peng
P
Lü
2 School of Pharmacy, Jiangsu University , Zhenjiang, China .
Yuhua
Y
Yang
2 School of Pharmacy, Jiangsu University , Zhenjiang, China .
Yajun
Y
Wei
2 School of Pharmacy, Jiangsu University , Zhenjiang, China .
Xiaojing
X
Dong
2 School of Pharmacy, Jiangsu University , Zhenjiang, China .
Dewan
D
Ren
1 Institute of Life Sciences, Jiangsu University , Zhenjiang, China .
Keping
K
Chen
2 School of Pharmacy, Jiangsu University , Zhenjiang, China .
Hanqing
H
Liu
1 Institute of Life Sciences, Jiangsu University , Zhenjiang, China .
Zhigang
Z
Tu
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D005260:Female; D066257:Heparin-binding EGF-like Growth Factor / Q000737:chemistry* / Q000378:metabolism; D006801:Humans; D058990:Molecular Targeted Therapy; D011379:Prognosis
D000970:Antineoplastic Agents; D066257:Heparin-binding EGF-like Growth Factor
EGFR; HB-EGF; angiogenesis; breast cancer; targeted therapy; triple-negative breast cancer